Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Bone Marrow Transplant ; 46(1): 44-51, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20436517

ABSTRACT

SCF has been shown to synergize with G-CSF to mobilize CD34(+) PBPCs. In this study we report results from this combination after a phase II trial of 32 patients with malignant lymphoma randomized to receive recombinant methionyl human SCF (ancestim, r-metHuSCF) in combination with recombinant methionyl human G-CSF (filgrastim, r-metHuG-CSF) (experimental arm A) or routine chemotherapy plus filgrastim (conventional arm B). The primary objective was to evaluate the side effects and toxicity during priming and mobilization. The secondary objectives were efficacy by the level of blood-circulating PBPCs, the number of harvest days and the time to three-lineage engraftment after autografting. First, during priming 5 patients had 8 serious events, 4 in each arm. A summary of all adverse events revealed 30 (94%) patients suffering from 132 events of all grading. Second, neutropenia and thrombocytopenia was documented in arm B. Third, 9/14 (64%) patients in arm A reached the target of 5 million CD34(+) cells/kg body weight (bw) compared with 13/15 (87%) in arm B. The results represent the first randomized trial of growth factor plus chemotherapy priming and indicate that a formal phase III trial very unlikely may challenge chemotherapy plus r-metHuG-CSF priming in candidates for high-dose therapy.


Subject(s)
Graft Survival/drug effects , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Mobilization/methods , Lymphoma/therapy , Peripheral Blood Stem Cell Transplantation , Stem Cell Factor/analogs & derivatives , Transplantation Conditioning/methods , Adult , Aged , Antigens, CD34/blood , Drug Therapy, Combination/adverse effects , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/adverse effects , Hematopoietic Stem Cell Mobilization/adverse effects , Humans , Lymphoma/blood , Male , Middle Aged , Neutropenia/chemically induced , Neutropenia/prevention & control , Peripheral Blood Stem Cell Transplantation/adverse effects , Pilot Projects , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Stem Cell Factor/adverse effects , Stem Cell Factor/therapeutic use , Thrombocytopenia/chemically induced , Thrombocytopenia/prevention & control , Transplantation Conditioning/adverse effects , Transplantation, Autologous/adverse effects , Young Adult
2.
Perfusion ; 26(1): 45-50, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20736244

ABSTRACT

Blood flow during cardiopulmonary bypass (CPB) is calculated on body surface area (BSA). Increasing comorbidity, age and weight of today's cardiac patients question this calculation as it may not reflect individual metabolic requirement. The hypothesis was that a measured cardiac index (CI) prior to normothermic CPB is a better estimate. A cross-over study, with random allocation to CPB blood flow for 20 minutes based on either a calculation (2.4 L/min/m(2)) or on CI, with a switch to the opposite flow for another 20 minutes, was performed. Twenty-two elective cardiac surgery patients with normal ventricular function were included. Effect parameters were cerebral oxygenation, mixed venous saturation and arterial lactate. CI varied from 1.9 to 3.1 L/min/m(2) (median 2.4 L/min/m(2)). No differences in effect parameters were seen. In conclusion, a CPB blood flow based on an individual estimate did not improve cerebral and systemic oxygenation compared to a blood flow based on BSA.


Subject(s)
Blood Flow Velocity , Body Surface Area , Cardiopulmonary Bypass , Oxygen/blood , Aged , Cardiac Surgical Procedures , Cross-Over Studies , Female , Humans , Male , Oxygen Consumption
SELECTION OF CITATIONS
SEARCH DETAIL
...